-
Something wrong with this record ?
Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion
M. Vasatova, R. Pudil, V. Safka, T. Fejfar, T. Buchler, P. Hulek, V. Palicka,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
SAGE Publications Journals
from 1999-01-01 to 2015-12-31
SAGE Publications Journals
from 1999-01-01 to 2015-12-31
- MeSH
- Biomarkers blood metabolism MeSH
- Adult MeSH
- Liver Cirrhosis blood diagnosis metabolism mortality surgery MeSH
- Middle Aged MeSH
- Humans MeSH
- Multivariate Analysis MeSH
- Myocardium metabolism MeSH
- Prognosis MeSH
- ROC Curve MeSH
- Aged MeSH
- Portasystemic Shunt, Transjugular Intrahepatic * MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BACKGROUND: Transjugular intrahepatic portosystemic shunts (TIPSs) have become a widely accepted tool in the treatment of patients with symptomatic portal hypertension. The aim of our study was to assess the value of cardiac markers before and after TIPS insertion for the prediction of one-year mortality in cirrhotic patients. METHODS: The study population consisted of 55 patients (38 men and 17 women, aged 55.6 ± 8.9 y, range 37-74) with liver cirrhosis treated with transjugular portosystemic shunting. Biochemical markers were measured before and 24 h after TIPS. High-sensitivity cardiac troponin T (hs-cTnT) was tested by high-sensitivity immunoassay for Elecsys analyser (Roche Diagnostics). Concentrations of creatine kinase MB isoenzyme, myoglobin (MYO), glycogenphosphorylase BB isoenzyme (GPBB) and heart type of fatty acid binding protein (FABP) were measured by the Evidence Investigator protein biochip system (Randox Laboratories). RESULTS: In patients before TIPS insertion, hs-cTnT was increased above the cut-off (0.014 μg/L) in 39.2% of patients. Higher hs-cTnT and FABP concentrations were associated with poor survival in patients before TIPS (hs-cTnT: P = 0.018; FABP: P = 0.016). Twenty-four hours after the TIPS procedure, we found a significant elevation in serum GPBB in comparison with preprocedural values (P < 0.001). There was an association between postprocedural concentrations of cardiac markers (MYO, hs-cTnT, FABP) and overall survival. CONCLUSIONS: Measurement of cardiac markers, mainly hs-cTnT and FABP, may be useful for mortality prediction in cirrhotic patients after TIPS. Cardiac markers are better mortality predictors than other risk factors such as age, gender or Child-Pugh score.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031584
- 003
- CZ-PrNML
- 005
- 20131003092921.0
- 007
- ta
- 008
- 131002s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1258/acb.2012.012097 $2 doi
- 035 __
- $a (PubMed)23431482
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vasatova, Martina $u Institute of Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine, University Hospital, Sokolska 581, Hradec Kralove 50005. martina.vasatova@fnhk.cz
- 245 10
- $a Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion / $c M. Vasatova, R. Pudil, V. Safka, T. Fejfar, T. Buchler, P. Hulek, V. Palicka,
- 520 9_
- $a BACKGROUND: Transjugular intrahepatic portosystemic shunts (TIPSs) have become a widely accepted tool in the treatment of patients with symptomatic portal hypertension. The aim of our study was to assess the value of cardiac markers before and after TIPS insertion for the prediction of one-year mortality in cirrhotic patients. METHODS: The study population consisted of 55 patients (38 men and 17 women, aged 55.6 ± 8.9 y, range 37-74) with liver cirrhosis treated with transjugular portosystemic shunting. Biochemical markers were measured before and 24 h after TIPS. High-sensitivity cardiac troponin T (hs-cTnT) was tested by high-sensitivity immunoassay for Elecsys analyser (Roche Diagnostics). Concentrations of creatine kinase MB isoenzyme, myoglobin (MYO), glycogenphosphorylase BB isoenzyme (GPBB) and heart type of fatty acid binding protein (FABP) were measured by the Evidence Investigator protein biochip system (Randox Laboratories). RESULTS: In patients before TIPS insertion, hs-cTnT was increased above the cut-off (0.014 μg/L) in 39.2% of patients. Higher hs-cTnT and FABP concentrations were associated with poor survival in patients before TIPS (hs-cTnT: P = 0.018; FABP: P = 0.016). Twenty-four hours after the TIPS procedure, we found a significant elevation in serum GPBB in comparison with preprocedural values (P < 0.001). There was an association between postprocedural concentrations of cardiac markers (MYO, hs-cTnT, FABP) and overall survival. CONCLUSIONS: Measurement of cardiac markers, mainly hs-cTnT and FABP, may be useful for mortality prediction in cirrhotic patients after TIPS. Cardiac markers are better mortality predictors than other risk factors such as age, gender or Child-Pugh score.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a biologické markery $x krev $x metabolismus $7 D015415
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a jaterní cirhóza $x krev $x diagnóza $x metabolismus $x mortalita $x chirurgie $7 D008103
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a multivariační analýza $7 D015999
- 650 _2
- $a myokard $x metabolismus $7 D009206
- 650 12
- $a transjugulární intrahepatální portosystémový zkrat $7 D019168
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a ROC křivka $7 D012372
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pudil, Radek $u -
- 700 1_
- $a Safka, Vaclav $u -
- 700 1_
- $a Fejfar, Tomas $u -
- 700 1_
- $a Buchler, Tomas $u -
- 700 1_
- $a Hulek, Petr $u -
- 700 1_
- $a Palicka, Vladimir $u -
- 773 0_
- $w MED00000421 $t Annals of clinical biochemistry $x 1758-1001 $g Roč. 50, č. Pt 2 (2013), s. 122-6
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23431482 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20131003093438 $b ABA008
- 999 __
- $a ok $b bmc $g 995671 $s 830029
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 50 $c Pt 2 $d 122-6 $i 1758-1001 $m Annals of clinical biochemistry $n Ann Clin Biochem $x MED00000421
- LZP __
- $a Pubmed-20131002